Racephedrine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Racephedrine
DrugBank Accession Number
DB14752
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental
Structure
Weight
Average: 165.236
Monoisotopic: 165.115364107
Chemical Formula
C10H15NO
Synonyms
  • (+-)-Ephedrine
  • Ephedrine DL-form
  • Racephedrine

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Racephedrine can be decreased when used in combination with Acebutolol.
AlfuzosinThe therapeutic efficacy of Racephedrine can be decreased when used in combination with Alfuzosin.
AmitriptylineThe therapeutic efficacy of Racephedrine can be decreased when used in combination with Amitriptyline.
AmitriptylinoxideThe risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Racephedrine.
AmoxapineThe therapeutic efficacy of Racephedrine can be decreased when used in combination with Amoxapine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Chi FormulaCapsule4.2 mgOralNatures Sunshine Products, Inc.1995-12-312006-07-10Canada flag
EphedraCapsule8 mg / capOralChampion's Choice Advanced Nutrition Inc.1997-06-111999-08-28Canada flag
EphedraCapsule8 mgOralNatural Balance2002-01-142009-08-17Canada flag
Fyto-HB Tea - 10mg/pckKit; Liquid10 mg / pckOralFytoresearch Inc.1997-09-252002-11-14Canada flag
Pro-enz 99Tablet8 mgOralCountry Road Naturals Inc.2001-05-012003-07-08Canada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
03VRY66076
CAS number
90-81-3
InChI Key
KWGRBVOPPLSCSI-PSASIEDQSA-N
InChI
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m1/s1
IUPAC Name
(1S,2R)-2-(methylamino)-1-phenylpropan-1-ol
SMILES
CN[C@H](C)[C@@H](O)C1=CC=CC=C1

References

General References
Not Available
ChemSpider
9085
ChEMBL
CHEMBL2110656
ZINC
ZINC000000074840
Wikipedia
Ephedrine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral4.2 mg
CapsuleOral8 mg / cap
CapsuleOral8 mg
Kit; liquidOral10 mg / pck
TabletOral8 mg
CapsuleOral4 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility8.26 mg/mLALOGPS
logP1ALOGPS
logP1.32Chemaxon
logS-1.3ALOGPS
pKa (Strongest Acidic)13.89Chemaxon
pKa (Strongest Basic)9.52Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area32.26 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity49.69 m3·mol-1Chemaxon
Polarizability18.87 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kb-0900000000-4a2a7c918368930693fa
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0900000000-56b8f9c6cad6a483eb62
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014l-6900000000-125aac34eca51135b9d1
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0aor-5900000000-e23ee25dd8123c9b13ad
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9200000000-a1773c8925eed519e99d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a6u-9300000000-01a6c30b0567e12cc866
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-142.5514286
predicted
DarkChem Lite v0.1.0
[M+H]+143.0787286
predicted
DarkChem Lite v0.1.0
[M+Na]+142.7116286
predicted
DarkChem Lite v0.1.0

Drug created at March 05, 2019 17:14 / Updated at April 19, 2024 20:55